Sitagliptin
- Generic Name
- Sitagliptin
- Brand Names
- Janumet, Januvia, Ristaben, Steglujan, Tesavel, Velmetia, Xelevia, Sitagliptin SUN, Sitagliptin Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15F6N5O
- CAS Number
- 486460-32-6
- Unique Ingredient Identifier
- QFP0P1DV7Z
- Background
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar. Sitagliptin was granted FDA approval on Oct...
- Indication
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.
It is also used in combination with metformin or ertugliflozin.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Effects of Sitagliptin on Postprandial Lipemia in Men With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2012-12-11
- Lead Sponsor
- Laval University
- Target Recruit Count
- 36
- Registration Number
- NCT00660075
- Locations
- 🇨🇦
Laval University Medical Center, Quebec City, Quebec, Canada
Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart Failure
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2014-12-05
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 16
- Registration Number
- NCT00657280
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2013-07-19
- Target Recruit Count
- 451
- Registration Number
- NCT00642278
A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)
- Conditions
- Interventions
- First Posted Date
- 2008-03-17
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 514
- Registration Number
- NCT00637273
- Locations
- 🇲🇽
Research Site, Toluca, Mexico
A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)
- Conditions
- Interventions
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2017-01-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 146
- Registration Number
- NCT00631488
Beta-cell Function in Glucose Abnormalities and Acute Myocardial Infarction
- Conditions
- Interventions
- First Posted Date
- 2008-03-03
- Last Posted Date
- 2021-02-12
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 85
- Registration Number
- NCT00627744
- Locations
- 🇸🇪
Karolinska University Hospital Solna, Stockholm, Sweden
🇸🇪Karolinska Institutet, Stockholm, Sweden
Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 148
- Registration Number
- NCT00616811
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸Anasazi Internal Medicine, Phoenix, Arizona, United States
Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)
- First Posted Date
- 2007-10-10
- Last Posted Date
- 2015-08-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 273
- Registration Number
- NCT00541775
Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)
- Conditions
- Interventions
- First Posted Date
- 2007-07-31
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 129
- Registration Number
- NCT00509236
Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)
- Conditions
- Interventions
- First Posted Date
- 2007-07-31
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 426
- Registration Number
- NCT00509262
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.